After a flurry of news over the past few months, the Q4 report offered little of substance. The outlook for improvement was also of limited informative value, as the decision to choose a publishing partner or to self-publish Condor and Control 2 will have a material impact on Remedy's near-term figures. This is an important long-term strategic decision that will shape the company's direction for the next decade. Given the potential of the Control franchise, we believe that the company will work towards self-publishing both or one of the projects, which will also require additional funding. Remedy's long-term potential is very attractive and at the current valuation we see the risk/reward ratio as a reason to stay long with the stock.